A Phase I/II Dose-Escalation and Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors With a KRAS G12D Mutation
Latest Information Update: 05 Jun 2025
At a glance
- Drugs GDC 7035 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Genentech
Most Recent Events
- 04 Apr 2025 Planned End Date changed from 30 Nov 2028 to 31 May 2028.
- 04 Apr 2025 Planned primary completion date changed from 30 Nov 2028 to 31 May 2028.
- 09 Dec 2024 Status changed from not yet recruiting to recruiting.